Stocks · News reference

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Aug 6, 2026, 12:33 PMVandana Singh

Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 6, 2026, 8:30 PMSEC EDGAR
8-K filing — Sonoma Pharmaceuticals, Inc. (SNOA)
Filed: 2026-10-06 AccNo: 0001683168-26-007657 Size: 663 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
SNOA
BenzingaAug 6, 2026, 1:03 PMBenzinga Newsdesk
Sonoma Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q1 financial results.
SNOA
BenzingaAug 6, 2026, 12:34 PMBenzinga Newsdesk
Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoY
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.09) per share. This is a 88.16 percent increase over losses of $(0.76) per share from the same period last year. The company reported $6.406 million
SNOA